首页> 外文期刊>Clinical and experimental hypertension: CEH >Treatment with nicardipine protects brain in an animal model of hypertension-induced damage.
【24h】

Treatment with nicardipine protects brain in an animal model of hypertension-induced damage.

机译:尼卡地平的治疗可以保护高血压诱发的动物模型中的大脑。

获取原文
获取原文并翻译 | 示例
           

摘要

Control of blood pressure protects from the development of cerebrovascular lesions and vascular dementia (VaD). This study has assessed the influence of treatment with the dihydropyridine-type Ca2+ antagonist nicardipine on brain microanatomical changes in spontaneously hypertensive rats (SHR). SHR were treated from 16th to 26th week of age with hypotensive (3 mg/Kg/day) or non-hypotensive (0.1 mg/Kg/day) doses of nicardipine, with the non-dihydropyridine-type vasodilator hydralazine (10 mg/kg/day) or with vehicle (control group). Untreated age-matched Wistar Kyoto (WKY) rats were used as a normotensive reference group. Brain volume, number of neurons, glial fibrillary-acidic protein (GFAP)-immunoreactive astrocytes and neurofilament 200 KDa (NFP)-immunoreactivity (IR) were assessed in frontal and occipital cortex, hippocampus and striatum. A decrease of volume and number of nerve cells and a loss of NFP-IR was found in the frontal and occipital cortex and in the CA1 subfield of hippocampus and in the striatum of SHR. Treatment with nicardipine countered microanatomical changes occurring in SHR, whereas hydralazine displayed a less pronounced effect. Comparatively, the non-hypotensive dose of nicardipine was less active than the hypotensive one. The observation that equihypotensive doses of nicardipine or hydralazine did not protect brain in the same way from hypertensive brain damage suggests that lowering blood pressure is per se not enough for affording neuroprotection. The demonstration of neuroprotective effect of nicardipine suggests an use of the compound in situations in which hypertension is accompanied by the risk of brain damage.
机译:血压控制可防止脑血管病变和血管性痴呆(VaD)的发展。这项研究评估了用二氢吡啶类Ca2 +拮抗剂尼卡地平治疗对自发性高血压大鼠(SHR)脑显微解剖学变化的影响。在第16周至第26周龄,对SHR进行降压(3 mg / Kg /天)或非降压(0.1 mg / Kg /天)尼卡地平治疗,并使用非二氢吡啶类血管扩张剂肼苯哒嗪(10 mg / kg /天)或车辆(对照组)。未治疗的年龄匹配的Wistar Kyoto(WKY)大鼠用作血压正常对照组。评估额叶和枕叶皮层,海马和纹状体的脑容量,神经元数量,神经胶质纤维酸性蛋白(GFAP)-免疫反应性星形胶质细胞和神经丝200 KDa(NFP)-免疫反应性(IR)。在额叶和枕叶皮层以及海马CA1亚区和SHR纹状体中发现神经细胞的数量和数量减少,NFP-IR丢失。尼卡地平的治疗抵消了SHR中发生的微解剖学变化,而肼屈嗪显示的效果较差。相比之下,非降血压药物尼卡地平的活性低于降血压药物。降血压剂量的尼卡地平或肼屈嗪不能以相同的方式保护大脑免受高血压性脑损伤的观察结果表明,降低血压本身不足以提供神经保护作用。尼卡地平具有神经保护作用的证据表明,该化合物可在高血压伴有脑损伤风险的情况下使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号